New NICE guidance for anti-migraine device

The National Institute for Health and Care Excellence (NICE) has published guidance stating that Cefaly, a device for the treatment and prevention of migraine, can safely be used within the NHS.

Available since 2014, Cefaly is worn as a small headband that applies precise neurostimulation through an electrode on the forehead to stimulate the nerve involved in migraine activity. Patients wear the device for 20 minutes every day as a preventative measure and at the start of a migraine episode to reduce attacks. Cefaly is not associated with side effects and is said to be safe for use in children, pregnant and breastfeeding women and those with chronic medical conditions.

Simon Evans, chief executive of Migraine Action, said: “We welcome the NICE guidelines on the efficacy of the Cefaly device. Any new treatment for migraine sufferers will be well received by our members, particularly a non-pharmacological intervention, non-invasive treatment that can be used with existing medication.”

Recommended

Oral impact

Alprazolam misuse highlighted in young




This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Training Matters's Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.